Citadel Advisors’s Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock VHAQ.RT Stock Holding History

Citadel Advisors’s Portfolio VHAQ.RT Stock Details VHAQ.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,739	Closed	-$2K	–	15658
2022 Q3	$2K	Buy	15,739 +1,101	+8%	+$126	﹤0.01%	12429
2022 Q2	$1K	Sell	14,638 -736	-5%	-$98	﹤0.01%	12735
2022 Q1	$2K	Sell	15,374 -499,900	-97%	-$79.8K	﹤0.01%	13448
2021 Q4	$95K	Sell	515,274 -13	-0%	-$3	﹤0.01%	12772
2021 Q3	$108K	Sell	515,287 -96	-0%	-$21	﹤0.01%	12781
2021 Q2	$139K	Sell	515,383 -5,449	-1%	-$1.12K	﹤0.01%	12583
2021 Q1	$94K	Buy	+520,832	New	+$122K	﹤0.01%	12522

Other funds holding VHAQ.RT

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Citadel Advisors's VHAQ.RT Position: Q4 2022 in Review

Citadel Advisors sold out of Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock (VHAQ.RT) in Q4 2022, closing a stake of 15,739 shares — an estimated $2K sold.

Citadel Advisors first reported a position in VHAQ.RT in Q1 2021 and held it in 7 quarters. The position peaked at $139K in Q2 2021. 27 funds tracked by Wall St. Rank hold VHAQ.RT as of Q4 2022.

Citadel Advisors reported no remaining Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 15,739 Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock shares in Q4 2022, an estimated $2K.
Citadel Advisors first reported a position in Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock in Q1 2021 and held it in 7 quarters.
Citadel Advisors's Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock position peaked at $139K in Q2 2021.
27 funds tracked by Wall St. Rank held Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.